The exciting part is that it is a Worlds first and has been validated with clinical trials.
'the world's first clinically-tested, regulatory Approved smartphone application for respiratory disease diagnosis and management.'
This is ISN and ALT all over again but the big advantage it will have over those two is the fact that it doesn't require any additional hardware.
ISN required the wheezeometer, ALT required the pericoach.
NLS only requires what we already have, a smartphone.
'ResApp's technology is unique in that it does not require the purchase or use of additional hardware. Only the patients smartphone is needed.'
- Forums
- ASX - Day Trading
- daytraders after market lounge 2nd Oct
The exciting part is that it is a Worlds first and has been...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online